Jeffrey Boyd

Partner, Global Healthcare & Life Sciences Practice • Heidrick & Struggles

Jeff Boyd is a partner in Heidrick & Struggles’ New York office and a member of the Healthcare & Life Sciences Practice with strong alignment to the Supply Chain & Operations Officers Practice. He also co-leads the Life Science Tools & Services sector. Jeff helps leading life sciences companies advance their operational strategies, lead change effectively, and solve complex organizational challenges through effective talent solutions. His expertise ranges from research and early development through commercialization in biotech, pharma, and life science tools and services.

Prior to joining Heidrick & Struggles, Jeff was vice president and head of technical operations for Novartis, where he worked in the cell and gene therapy unit and oversaw the operations and supply chain functions, ultimately supporting the commercialization of the first CAR-T therapy in the world.

Prior to Novartis, he worked at Lonza for 13 years, progressing from shop floor supervision to global operational leadership roles with a variety of different technologies, including diagnostic and research products, small molecules, biologics, and cell and gene therapy contract development and manufacturing. He also spent five years leading global human resources for the bioscience sector, where he managed several transformative merger and acquisition projects in the United States, Europe, and Asia, including responsibilities spanning from due diligence through integration, with a focus on the cultural assimilation component.

Jeff worked as a distribution and warehousing manager in life sciences prior to joining Lonza. Earlier in his career, he held operational and human resources leadership roles in the food industry.

Also Speaking

Ryan Leahy

Vice President of Research • Phacilitate

Martin Maiers

Vice President, Research • Be The Match BioTherapies

Li Ou

Vice President • Genemagic Bio

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.